Understanding Your Blood Pressure Goal: A Patient's Guide to Hypertension Treatment Targets

Table of Contents

• Key Points
• Introduction: Why Blood Pressure Treatment Matters
• How Blood Pressure Should Be Measured (And Why It Matters)
• Understanding Risk: Absolute vs. Relative Risk
• Blood Pressure Goals for Higher-Risk Patients
• The SPRINT Trial: Key Evidence for Intensive Blood Pressure Control
• What the SPRINT Results Show
• Clinical Implications for Patients
• Limitations: What the Research Couldn't Prove
• Recommendations for Patients
• Frequently Asked Questions
• Source Information

Key Points

• Routine office blood pressure readings can be 5–15 mmHg higher than standardized methods, so doctors prefer the latter for setting targets.
• Treatment decisions are based on absolute risk reduction: high-risk patients gain more from intensive blood pressure lowering than low-risk patients.
• In the SPRINT trial, targeting systolic pressure below 120 mmHg reduced cardiovascular events and death in high-risk non-diabetic adults.
• Intensive blood pressure lowering may increase acute kidney injury, fainting, and low sodium, but most issues resolve and serious falls were not increased.
• Higher-risk patients—including those with heart disease, diabetes, CKD, or age over 65—may benefit from lower goals, but shared decision-making with your doctor is essential.

Introduction: Why Blood Pressure Treatment Matters

High blood pressure (hypertension) is one of the most common health conditions worldwide. In fact, treating high blood pressure is one of the most frequent reasons that non-pregnant adults visit their doctor's office, and it's among the top reasons people take prescription medications. This topic is reviewed by experts at UpToDate, a leading physician reference used by doctors around the world.

This article covers two key questions for anyone living with hypertension: When should blood pressure medication be started, and what blood pressure number should you aim for? The answers depend on several factors, including how your blood pressure is measured and your personal risk for future heart problems (cardiovascular events) such as heart attacks, strokes, and heart failure.

Your doctor will consider many other aspects of hypertension, including risk factors, diagnosis, proper measurement technique, lifestyle changes (diet, salt restriction, weight loss, and exercise), and which specific medication is best for you. These are all important pieces of the puzzle, but this article focuses specifically on the blood pressure target you should be aiming for.

How Blood Pressure Should Be Measured (And Why It Matters)

One of the most important things to understand is that blood pressure targets depend heavily on how your blood pressure is measured. The method used can make a big difference in the numbers you see.

There are two broad categories of blood pressure measurement described by the experts:

• "Routine" (typical/casual) office blood pressure – This is the non-preferred method that is most commonly used worldwide. It involves measuring blood pressure once at the beginning of an office visit, often with the care provider in the room, and usually without proper patient preparation (such as having an empty bladder, sitting quietly with both feet on the floor for 3–5 minutes, not talking during the measurement, or using the correct cuff size). Because of the lack of standardization, these readings can vary widely from office to office and even between providers. This method is faster and easier, which is why it's used 90% of the time.
• "Non-routine" standardized methods (the preferred approach) – These four methods provide readings that are much closer to your true daytime blood pressure and were used in nearly all major outcome trials in hypertension:
  1. Standardized office-based measurement – This doesn't require special equipment (it can be done manually or with an automated device), but it does require proper patient preparation and proper technique, including resting quietly for several minutes before the reading.
  2. Automated oscillometric blood pressure monitoring (AOBPM) – This uses a specialized device programmed to take and average multiple consecutive readings after you've rested in a seated position for about five minutes. The care provider starts the machine and then leaves the room. This technique was used in the famous SPRINT trial (discussed below).
  3. Home blood pressure monitoring – You measure your own blood pressure at home with an automated device that has been checked for accuracy in the doctor's office. Typically, multiple readings are taken daily over several consecutive days and then averaged. A common approach is to take 2–4 readings daily for 5–7 days before your clinic visit.
  4. Ambulatory blood pressure monitoring (ABPM) – You wear a device for 24 hours that takes blood pressure readings automatically every 15–30 minutes during the day and every 30–60 minutes during sleep. This gives a complete picture of your blood pressure over a full day and night.

Why does this matter so much? Because on average, routine office measurements are 5 to 15 mmHg higher than non-routine standardized measurements. This gap exists because the "white coat" effect (blood pressure rising due to anxiety about being in a medical setting) is often present, and because routine measurements are taken without proper preparation and technique.

Some studies have shown even more dramatic differences between the two methods. However, it's critical to understand that this average difference applies to populations, not necessarily to you individually. Some people don't experience a white coat effect at all, so there is some uncertainty when setting goals based on the measurement method. The takeaway is simple: ideally, treatment decisions should be based on one of the preferred, standardized methods rather than a casual reading taken at the start of an office visit.

Understanding Risk: Absolute vs. Relative Risk

One of the most important concepts in blood pressure management is the difference between relative risk reduction and absolute risk reduction. This sounds technical, but it's actually quite intuitive once explained.

Relative risk reduction means the percentage by which a treatment lowers your chances of an event compared with not taking the treatment. Absolute risk reduction is the actual percentage-point difference in your personal risk. The experts explain that treatment decisions should be made based on the absolute benefits and harms, not just the relative numbers.

Here's a concrete example used in the original article. Imagine that lowering blood pressure by 10/5 mmHg produces a 20% relative risk reduction for major cardiovascular events. Now consider two different patients:

• Patient 1: A 50-year-old, non-smoking, non-diabetic African-American woman with total cholesterol of 190 mg/dL, HDL (good) cholesterol of 45 mg/dL, and systolic blood pressure of 135 mmHg. Her predicted 10-year risk of a major cardiovascular event is 3%.
• Patient 2: A 50-year-old, diabetic African-American woman who smokes, has total cholesterol of 200 mg/dL, HDL cholesterol of 35 mg/dL, and systolic blood pressure of 135 mmHg. Her predicted 10-year risk of a major cardiovascular event is 20%.

Both patients get a 20% relative risk reduction from treatment. But the actual benefit they experience is very different:

• Patient 1's risk drops from 3% to 2.4% — an absolute risk reduction of only 0.6%. In a group of patients like her, 167 people would need to take blood pressure medication for 10 years to prevent one heart attack, stroke, or other major event.
• Patient 2's risk drops from 20% to 16% — an absolute risk reduction of 4.0%. In a group of patients like her, only 25 people would need to take medication for 10 years to prevent one event.

This example shows that the same treatment can have very different real-world value depending on your starting risk. The higher your baseline risk, the more you stand to gain from treatment.

This concept is backed by research. A 2014 meta-analysis of 11 randomized trials comparing antihypertensive therapy with placebo looked at patients stratified by their estimated 5-year risk of major cardiovascular events (heart attack, stroke, or heart failure), using age, sex, body mass index, prior history of cardiovascular disease, smoking, and diabetes status. The results showed:

• In patients with the highest cardiovascular risk (5-year risk greater than 21%), the absolute risk reduction from treatment was 3.8%, meaning 26 patients needed to be treated for 5 years to prevent one event.
• In patients with the lowest risk (5-year risk of about 6%), the absolute risk reduction was 1.4%, meaning 71 patients needed treatment for 5 years to prevent one event.

The relative risk reduction was similar across all risk levels, but the absolute benefit was much larger for high-risk patients. This is why doctors weigh your personal risk profile so heavily when deciding how aggressively to treat your blood pressure.

Blood Pressure Goals for Higher-Risk Patients

The experts recommend more aggressive (lower) blood pressure targets for patients who are at higher risk for future cardiovascular events. You are considered higher-risk if you have one or more of the following characteristics:

• Established atherosclerotic cardiovascular disease (prior history of coronary disease, prior stroke or transient ischemic attack [TIA, sometimes called a "mini-stroke"], or documented peripheral arterial disease)
• Heart failure
• Diabetes mellitus
• Chronic kidney disease (CKD)
• Age over 65 years
• Multiple cardiovascular risk factors with an estimated 10-year risk of future cardiovascular events of 10% or greater (your doctor can calculate this with a risk calculator)

Patients without any of these characteristics are considered lower-risk, and a less intensive goal is recommended for them.

Patients with Established Atherosclerotic Cardiovascular Disease

For patients with established atherosclerotic cardiovascular disease (a prior history of coronary artery disease, cerebrovascular disease, or peripheral arterial disease), the experts recommend a goal blood pressure of 120 to 125/<80 mmHg when measured using the preferred "non-routine" methods (standardized office measurement, AOBPM, home blood pressure monitoring, or ABPM). If routine office measurements are used, the goal is slightly higher: 125 to 130/<80 mmHg. This accounts for the fact that routine measurements tend to run 5–15 mmHg higher.

The strongest evidence supporting this target comes from the SPRINT trial, which is described in detail below.

The SPRINT Trial: Key Evidence for Intensive Blood Pressure Control

The Systolic Blood Pressure Intervention Trial (SPRINT) is one of the most important studies ever conducted on blood pressure treatment. It was a large, multicenter, randomized, open-label trial performed in the United States, and its findings have shaped how doctors treat hypertension in higher-risk patients.

Who Was Enrolled in SPRINT?

SPRINT enrolled 9,361 patients aged 50 years or older. More than 90% were already taking antihypertensive medication at the start of the trial. To be included, patients needed a systolic blood pressure of 130 to 180 mmHg plus at least one of the following additional risk factors:

• Age 75 years or older
• Clinically evident cardiovascular disease (previously documented coronary, peripheral arterial, or cerebrovascular disease, except stroke)
• Subclinical cardiovascular disease (elevated coronary artery calcification score on a CT scan, left ventricular hypertrophy, or an ankle-brachial index below 0.9)
• Estimated glomerular filtration rate (eGFR) of 20 to 59 mL/min/1.73 m² (indicating moderately reduced kidney function)
• 10-year Framingham Risk Score of 15% or greater

SPRINT excluded patients with diabetes, symptomatic heart failure, a history of stroke, or proteinuria (1 g/day or more of total protein or 600 mg/day or more of albumin in the urine). Nursing home residents were also excluded.

Baseline Characteristics of SPRINT Participants

At the start of the trial, the average age of participants was 68 years, the average body mass index (BMI) was 30 kg/m², the average Framingham 10-year risk score was 20%, and the average blood pressure was 140/78 mmHg. Clinical or subclinical cardiovascular disease was present in 22% of patients.

How the Trial Was Conducted

Patients were randomly assigned to one of two treatment groups:

• Standard treatment group: targeting systolic blood pressure to <140 mmHg
• Intensive treatment group: targeting systolic blood pressure to <120 mmHg

In both groups, the diastolic blood pressure goal was <90 mmHg. Blood pressure during the trial was measured using attended or unattended AOBPM, the preferred standardized method discussed earlier.

Treatment typically started with an ACE inhibitor (angiotensin-converting enzyme inhibitor) or an ARB (angiotensin receptor blocker) — but never both — a long-acting calcium channel blocker (usually amlodipine), or a thiazide-like diuretic (specifically chlorthalidone rather than hydrochlorothiazide), or a combination of these medications. Additional drugs were added as needed to reach the target.

Importantly, in the standard treatment group, medications were actively withdrawn if systolic blood pressure fell below 130 to 135 mmHg, even if the patient felt fine. In both groups, medications were adjusted or stopped if adverse effects developed.

What happened in the first year? About half of the patients in the intensive-treatment group attained a systolic pressure below 120 mmHg. The average systolic pressures at one year were 121 mmHg in the intensive group and 136 mmHg in the standard group. The average number of antihypertensive medications used was 2.8 in the intensive group and 1.8 in the standard group.

What the SPRINT Results Show

The trial was halted early for benefit after a median follow-up of 3.33 years — in other words, the benefits of intensive treatment were so clear that the researchers felt it was no longer ethical to continue having the standard group follow the less intensive target. Here are the key findings:

Major Benefits of Intensive Blood Pressure Control

• Primary endpoint reduced: The primary endpoint was a combination (composite) of heart attack (myocardial infarction), acute coronary syndrome, stroke, heart failure, or death from cardiovascular causes. This occurred in 5.6% of the intensive group compared with 7.6% of the standard group — a significant reduction.
• Heart failure reduced: Rates were 1.4% in the intensive group versus 2.2% in the standard group.
• Heart attacks reduced: Rates were 2.2% versus 3.0%.
• Cardiovascular deaths reduced: Rates were 0.9% versus 1.5%.
• Overall mortality reduced: Death from any cause was 3.5% in the intensive group versus 4.6% in the standard group.
• Benefits in patients with known cardiovascular disease: Among those with heart or blood vessel disease at baseline, the primary endpoint occurred in 11.0% of the intensive group versus 13.3% of the standard group, although this difference was not statistically significant (meaning it could have been due to chance).

Brain Health Benefits

Intensive blood pressure control also showed benefits for the brain. Over a median follow-up of 5.1 years, intensive treatment reduced the rate of mild cognitive impairment (6.1% versus 7.5%). It also reduced the accumulation of cerebral white matter lesions — small areas of brain damage visible on MRI scans that are associated with cognitive decline and stroke risk.

There was no increase in the development of dementia in the intensive group. Notably, there were also no differences between treatment groups in physical and mental health-related quality of life, symptoms of depression, or satisfaction with care.

Side Effects and Safety Considerations

Intensive treatment was not without risks. The following side effects occurred more frequently in the intensive group:

• Acute kidney injury (AKI): Occurred in 3.8% of the intensive group versus 2.3% of the standard group. However, in the majority of patients, the AKI was mild — 61% had stage 1 AKI and 17% had stage 2. Importantly, about 95% of AKI cases completely or partially resolved. Mild to moderate AKI typically doesn't require reducing blood pressure medication unless hyperkalemia (high potassium) is also present.
• New chronic kidney disease (CKD): Defined as a substantive decline in eGFR from ≥60 to <60 mL/min/1.73 m², new CKD developed in 3.7% of the intensive group versus 1.0% of the standard group. However, this increase in creatinine (a waste product used to measure kidney function) during intensive blood pressure lowering is thought to reflect a benign, functional, and reversible change in GFR due to reduced blood flow rather than actual kidney damage. In fact, levels of kidney injury biomarkers were lower, not higher, in the intensive group, supporting this interpretation.
• Fainting (syncope): Occurred in 3.2% of the intensive group versus 2.1% of the standard group.
• Low blood sodium (hyponatremia): Occurred in 4.0% of the intensive group versus 2.2% of the standard group.

Reassuringly, the rates of injurious falls (falls serious enough to require emergency department evaluation or hospitalization) were similar between the two groups.

Clinical Implications for Patients

What does this all mean for you? The findings from SPRINT suggest that, among older, hypertensive, non-diabetic adults who are at high risk for cardiovascular disease, targeting systolic blood pressure to below 120 mmHg (measured with AOBPM) can reduce mortality and prevent serious cardiovascular events.

The authors of the original article note that lower blood pressure targets in higher-risk groups are relevant to a large segment of the population. Pursuing more intensive blood pressure lowering in such patients is likely to be cost effective, even though it requires more medication and additional monitoring.

There are strong data supporting treatment decisions in certain patient populations, including patients with severely elevated blood pressure (for example, diastolic pressure of ≥110 mmHg), patients at high cardiovascular risk, and older adults. However, the data are weaker and largely indirect for many other patient populations. This is why your doctor will use good clinical judgment and engage in shared decision-making with you — meaning you work together to weigh the potential benefits and risks of more intensive treatment based on your individual circumstances.

The authors also emphasize that the more aggressive goals apply specifically to higher-risk patients. For lower-risk patients, a less intensive goal is appropriate, because the absolute benefit of very aggressive treatment is smaller while the inconvenience, cost, and potential for side effects remain.

Limitations: What the Research Couldn't Prove

While SPRINT was a landmark trial, the authors are careful to point out several factors that may affect how its findings apply to real-world patients:

• Patients in SPRINT were healthier than typical patients: Many patients in the trial had controlled blood pressure at baseline. In general, people who enroll in clinical trials are healthier than other patients with the same condition. This means the rate of side effects reported in SPRINT may be an underestimate of what happens when intensive treatment is used in routine practice, where patients often have more health problems.
• More medications may be needed: Patients in routine practice may require more blood pressure medications than SPRINT participants did. The average was about three medications in the intensive treatment group, and about one-fourth required four or more. Taking more medications could increase the risk of side effects.
• Measurement method differences: Blood pressure in SPRINT was measured using AOBPM (attended and unattended), which corresponds more closely with mean daytime blood pressure (from 24-hour ambulatory monitoring) than with the casual, routine office measurements typically performed in practice. Since routine measurements tend to be 5–15 mmHg higher, the goals in SPRINT don't translate directly to routine office readings. This is why the recommended goals are higher (125–130 mmHg) when routine office measurement is used.
• Diabetes and other conditions excluded: SPRINT excluded patients with diabetes, symptomatic heart failure, and stroke. Other trials provide guidance for those populations (the ACCORD trial, which studied intensive blood pressure control in people with diabetes, used similar AOBPM methodology), but the authors note that blood pressure goal trials using home blood pressure measurement or ABPM are lacking.
• Population vs. individual differences: The 5–15 mmHg difference between routine and non-routine measurement is an average across populations. Individual patients may not follow this pattern, and some don't experience a white coat effect at all. This creates uncertainty when setting goals for any given person.

Recommendations for Patients

Based on the expert guidelines and the research reviewed here, here are actionable steps you can discuss with your healthcare provider:

1. Ask about the preferred measurement method. Ask your doctor whether your blood pressure can be measured using one of the standardized preferred methods — standardized office-based measurement (with proper rest and technique), AOBPM, home blood pressure monitoring, or 24-hour ambulatory monitoring. These give a more accurate picture than a quick reading at the start of an appointment.
2. Consider home blood pressure monitoring. If you monitor at home, take 2–4 readings daily for 5–7 days before your clinic visit, using a properly validated automated device. Bring your average readings to your appointment. Use proper technique: sit quietly for 5 minutes with both feet on the floor, no talking, correct cuff size, and empty bladder.
3. Know your risk level. Ask your doctor to calculate your 10-year risk of cardiovascular events. If you have a 10-year risk of 10% or higher — or if you have established heart or blood vessel disease, heart failure, diabetes, chronic kidney disease, or are over 65 — you may benefit from a more intensive blood pressure goal.
4. Understand your target number. If you are a higher-risk patient, your goal may be around 120–125/<80 mmHg using preferred measurement methods, or 125–130/<80 mmHg using routine office measurements. If you are lower-risk, a less intensive goal is appropriate.
5. Expect a combination of medications. Reaching lower blood pressure goals often requires more than one medication — the average in SPRINT's intensive group was about three drugs. This is normal and expected; don't be discouraged if you need multiple medications.
6. Watch for side effects. More intensive blood pressure lowering can cause dizziness, fainting, low sodium, or changes in kidney function tests. While the vast majority of these issues resolve, you should report any concerning symptoms to your doctor promptly. The risk of serious falls was not increased in SPRINT, which is reassuring.
7. Be an active participant. Because the evidence is strong for some patient groups but weaker for others, shared decision-making with your doctor is essential. Discuss your personal values, lifestyle, medication tolerability, and preferences. A goal that works well for one person may not be right for another.

The bottom line: blood pressure treatment saves lives, and more intensive treatment can provide substantial additional benefits for patients at higher risk. The key is to use accurate measurement methods, know your personal risk, and work with your doctor to find the target that gives you the best balance of benefit and safety.

Frequently Asked Questions

What is the difference between routine and standardized blood pressure measurement?

Routine office readings are taken quickly, without strict preparation, and can run 5–15 mmHg higher than preferred methods. Standardized approaches—such as automated devices, home monitoring, or 24-hour ambulatory monitoring—require rest and proper technique, giving readings closer to your true daytime blood pressure. Doctors prefer these for setting treatment goals.

Why might my doctor recommend a lower blood pressure target for me?

Lower targets are advised for people at higher risk of heart attacks, strokes, or heart failure. This includes those with established heart or blood vessel disease, diabetes, chronic kidney disease, heart failure, age over 65, or a 10-year risk score of 10% or higher. For lower-risk patients, a less intensive goal is appropriate because absolute benefit is smaller.

What did the SPRINT trial show about intensive blood pressure control?

In SPRINT, over 9,300 high-risk adults aged 50+ without diabetes were randomly assigned to a systolic target below 120 or below 140 mmHg. Intensive treatment significantly reduced heart attacks, heart failure, cardiovascular deaths, and overall mortality. It also lowered mild cognitive impairment and brain white matter lesions. The trial was halted early for clear benefit.

What are the potential side effects of intensive blood pressure lowering?

In the SPRINT trial, intensive treatment increased rates of acute kidney injury, new chronic kidney disease, fainting, and low blood sodium compared with standard treatment. Most kidney issues were mild and resolved or partially resolved. Serious injurious falls were not increased. If you experience dizziness, fainting, or other symptoms, tell your doctor promptly.

How should I measure my blood pressure at home?

Use a validated automated device. Take 2–4 readings daily for 5–7 days before your clinic visit, then average them. Sit quietly for 5 minutes with both feet on the floor, no talking, use the correct cuff size, and empty your bladder first. Bring these averages to your appointment to help guide treatment decisions.

What is the difference between absolute and relative risk reduction?

Relative risk reduction is the percentage by which treatment lowers your chance of an event. Absolute risk reduction is the actual percentage-point drop in your personal risk. For example, a 20% relative reduction may mean only a 0.6% absolute benefit in a low-risk patient but a 4.0% benefit in a high-risk patient. Your doctor uses absolute benefit to decide treatment intensity.

What blood pressure goal is recommended for patients with established heart or blood vessel disease?

For these higher-risk patients, experts recommend a goal of 120–125/<80 mmHg when measured with preferred standardized methods, such as automated or home monitoring. If routine office measurements are used, the goal is slightly higher: 125–130/<80 mmHg. This accounts for the tendency of routine readings to be 5–15 mmHg higher.

Source Information

Original article title: Goal blood pressure in adults with hypertension - UpToDate

Authors: Johannes FE Mann, MD, and Karl F Hilgers, MD

Section editors: George L Bakris, MD; William B White, MD; Scott E Kasner, MD; David M Nathan, MD

Deputy editors: John P Forman, MD, MSc; Karen Law, MD

Publication details: UpToDate, literature review current through April 2023; topic last updated February 8, 2023. The article includes the SPRINT trial (Systolic Blood Pressure Intervention Trial) and a 2014 meta-analysis of 11 randomized trials as key evidence.

Note: This patient-friendly article is based on peer-reviewed research and expert clinical guidelines. It is provided for educational purposes and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult your healthcare provider with questions about your blood pressure management.